Trends and Updates in IBDAppraising the Therapeutic Armamentarium in Moderate and Severe Disease
Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF, et al. Lancet. 2018;390(10114):2779-2789.
Coskun M, et al. Pharmacol Res. 2013;76:1-8.
Kim DH, Cheon JH. Immune Netw. 2017;17(1):25-40.
De Vries LCS, et al. J Crohns Colitis. 2017;11(7):885-893.
Olivera P, et al. Expert Rev Clin Immunol. 2017;13(7):693-703.
Sandborn WJ, et al. N Engl J Med. 2017;377(5):496-497.
Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Vermeire S, et al. Lancet. 2017;389(10066):266-275.
Snapshot of IBD Today
The Current and Emerging Treatment Landscape of IBD
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
Got it? Treat it!
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Why It Matters in OB/GYN Practice Today
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
The PCP’s Role in HCV Elimination
Maximizing Your Role to Impact Patient Outcomes